15 ePosters and In-Person Presentations Will
Include Clinical Data on Blink™ NutriTears® Supplement for Dry
Eyes, Blink® Triple Care Lubricating Eye Drops and MIEBO®
(Perfluorohexyloctane Ophthalmic Solution)
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye
health company dedicated to helping people see better to live
better, today announced the presentation of 12 ePosters during the
American Optometric Association (AOA) Optometry’s Meeting ePoster
Session, taking place virtually May 29-30, 2024. The company will
also have three live presentations and host nine education events
during the in-person meeting, taking place in Nashville June 19-22,
2024.
The OnDemand ePosters will feature new data on the early
adoption of MIEBO and real-world patient experiences with Bausch +
Lomb INFUSE® Multifocal silicone hydrogel daily disposable contact
lenses. An evaluation of the performance of Biotrue® Hydration Plus
Multi-Purpose Solution among two different patient demographics –
soft contact lens wearers who are also frequent gamers and users
planning to stop wearing lenses due to discomfort – will also be
highlighted.
The live, in-person presentations will include clinical data
evaluating Blink NutriTears clinically proven nutritional
supplement for dry eyes*, which was selected by AOA as one of the
top five Optometry’s Meeting abstracts. Two other presentations
will showcase clinical evaluation data for Blink Triple Care
Lubricating Eye Drops, the first and only over-the-counter eye drop
with both hyaluronate and a nano-emulsion lipid in the unique
formula.
The complete list of scientific ePosters and live presentations,
as well as details for the featured education events, is as
follows:
e-Poster Presentations
- “A Multi-country Assessment of Satisfaction with a Spherical
Silicone Hydrogel Daily Disposable Contact Lens Among New Contact
Lens Wearers and Their Eyecare Professionals.” Reindel et al.
- “Comparison of Clinical Studies from the US and India of a
Multi-Ingredient Oral Supplement.” Gioia et al.
- “Early Adoption and Utilization of Perfluorohexyloctane for Dry
Eye Disease.” Alexander et al.
- “Evaluation of the Efficacy of a Novel Preservative-Free
Formulation of Brimonidine Tartrate Ophthalmic Solution.” Evans et
al.
- “Evaluation of the Safety of a Novel Preservative-Free
Formulation of Brimonidine Tartrate Ophthalmic Solution.” Evans et
al.
- “Frequent Gamers Tag a Novel Contact Lens Solution with High
Satisfaction” Shahidi et al.
- “Improvement in Non-Invasive Tear Break-Up Time after
Instillation of One Drop of Brimonidine Tartrate 0.025%.” Moore et
al.
- “Ocular Vasoconstrictors: Does Mechanism of Action Make a
Difference?” Moore et al.
- “On the Verge of Dropout: An In-Home Use Test of a Novel
Contact Lens Solution Among Planned Replacement Contact Lens
Wearers.” Shahidi et al.
- “Patient Performance Assessment with Multifocal Toric Silicone
Hydrogel Contact Lenses.” Rah et al.
- “Patient-reported Instillation Comfort and Eyedrop
Acceptability of Perfluorohexyloctane Ophthalmic Solution in
Pivotal Clinical Studies.” Cunningham et al.
- “Real-world Evaluation of a Daily Disposable Silicone Hydrogel
Multifocal Contact Lens.” Rah et al.
Live Presentations
- “Clinical Evaluation of a Novel Lipid-Containing Eye Drop.”
Coats et al.
- “Clinical Evaluation of a Multi-Ingredient Oral Supplement on
Dry Eye Symptoms and Tear Volume.” Gioia et al.
- “Comparison of a Novel Lipid Nano-Emulsion Eye Drop with an
Existing Lubricating Eye Drop.” Coats et al.
Featured Education Events
Wednesday, June 19
- “Showcasing Inflammation and IOP Control with Bausch + Lomb”
6:30 p.m. CDT at The Palm (140 5th Avenue South, Nashville, Tenn.)
Nora Lee Cothran, OD, FAAO, and Walter Whitley, OD, FAAO, will
discuss the benefits of using LOTEMAX® SM (loteprednol etabonate
ophthalmic gel), 0.38%, and VYZULTA® (latanoprostene bunod
ophthalmic solution), 0.024%. Register in advance.
Thursday, June 20
- “Showcasing Inflammation and IOP Control with Bausch + Lomb”
8:00-9:00 a.m. CDT at the Music City Center (201 Rep. John Lewis
Way S, Nashville, Tenn.; room #104AB) Richard Madonna, OD, and
Justin Schweitzer, OD, will discuss the benefits of using LOTEMAX
SM (loteprednol etabonate ophthalmic gel), 0.38%, and VYZULTA
(latanoprostene bunod ophthalmic solution), 0.024%.
- “NEW Breakthrough Supplement for Dry Eyes from Bausch + Lomb:
Blink NutriTears” 12:00-1:00 p.m. CDT at the Music City Center (201
Rep. John Lewis Way S, Nashville, Tenn.; room #104AB) Selina McGee,
OD, FAAO, and Julie Poteet, OD, will lead a conversation on the new
Blink NutriTears, a breakthrough, nutritional daily supplement for
dry eyes.
- “Current Thinking in Dry Eye Disease: Contemporary Perspectives
on a Complex Condition” 6:30-8:30 p.m. CDT at Morton’s Steakhouse
(618 Church Street, Nashville, Tenn.) Learn about MIEBO, the first
and only prescription eye drop that directly targets tear
evaporation, as well as XIIDRA® (lifitegrast ophthalmic solution),
5%, the only nonsteroid anti-inflammatory prescription eye drop
that can start to deliver dry eye symptom relief in just two
weeks.1-2 Register in advance.
- “A NightCap in Nashville with Blink NutriTears” 8:00-10:30 p.m.
(presentation at 9:00 p.m. CDT) at The Bell Tower (400th Ave. S,
Nashville, Tenn.) Join Cecelia Koetting, OD, FAAO, to lean about
Blink NutriTears clinically proven nutritional supplement for dry
eyes.
Friday, June 21
- “Rethinking Dry Eye Disease: A Contemporary Approach to a
Complex Condition” 8:00-9:00 a.m. CDT at the Music City Center (201
Rep. John Lewis Way S, Nashville, Tenn.; room #104AB) Cecelia
Koetting, OD, FAAO, and Nathan Lighthizer, OD, FAAO, will discuss
the benefits of and differences between MIEBO and XIIDRA.
- “The Science of Eye Beauty with LUMIFY EYE ILLUMINATIONS™”
12:40-1:00 p.m. CDT at the Music City Center (201 Rep. John Lewis
Way S, Nashville, Tenn.; Exhibit Hall, Eye Talks Stage) Join Selina
McGee, OD, FAAO, to learn about LUMIFY EYE ILLUMINATIONS, a
clinically proven specialty eye care line.
Saturday, June 22
- “A Family of Eye Care Products with Innovations for Every Stage
of Life” 9:00-10:00 a.m. CDT at the Music City Center (201 Rep.
John Lewis Way S, Nashville, Tenn.; room #104AB) Selina McGee, OD,
FAAO, Mitch Ibach, OD, FAAO, and John Womack, OD, will share
practical patient cases using products from across the Bausch +
Lomb consumer, vision care and pharmaceutical portfolios.
- “The Puzzle of Dry Eye: Targeted Approaches to a Multifactorial
Condition” 12:00-1:00 p.m. CDT at the Music City Center (201 Rep.
John Lewis Way S, Nashville, Tenn.; room #104AB) Learn about the
complex dry eye puzzle, Blink NutriTears, as well as MIEBO and
XIIDRA.
AOA’s Celebration of Optometry Event
Additionally, Bausch + Lomb is the title sponsor of AOA’s
Celebration of Optometry event, taking place at FGL House (120 3rd
Ave South, Nashville, Tenn.) at 7 p.m. CDT on Friday, June 21.
During the event, attendees will have the opportunity to learn
about Bausch + Lomb’s latest innovations, including Bausch + Lomb
INFUSE® for Astigmatism and Blink NutriTears.
Important Safety Information for MIEBO
INDICATION
MIEBO (perfluorohexyloctane ophthalmic solution) is used to
treat the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- Patients should remove contact lenses before using MIEBO and
wait for at least 30 minutes before reinserting.
- It is important for patients to use MIEBO exactly as
prescribed.
- It is not known if MIEBO is safe and effective in children
under the age of 18.
- The most common eye side effect seen in studies was blurred
vision (1% to 3 % of patients reported blurred vision and eye
redness).
You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or call
1-800-FDA-1088.
Click here for full Prescribing Information for
MIEBO.
WHAT IS XIIDRA?
XIIDRA (lifitegrast ophthalmic solution) 5% is a prescription
eye drop used to treat the signs and symptoms of dry eye
disease.
IMPORTANT SAFETY INFORMATION
Do not use XIIDRA if you are allergic to any of its ingredients.
Seek medical care immediately if you get any symptoms of an
allergic reaction.
The most common side effects of XIIDRA include eye irritation,
discomfort or blurred vision when the drops are applied to the
eyes, and an unusual taste sensation.
To help avoid eye injury or contamination of the solution, do
not touch the container tip to your eye or any surface. If you wear
contact lenses, remove them before using XIIDRA and wait for at
least 15 minutes before placing them back in your eyes.
It is not known if XIIDRA is safe and effective in children
under 17 years of age.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Click here for full Prescribing Information for
XIIDRA.
Important Safety Information for LOTEMAX SM
INDICATION
LOTEMAX SM (loteprednol etabonate ophthalmic gel) 0.38% is a
corticosteroid indicated for the treatment of post-operative
inflammation and pain following ocular surgery.
IMPORTANT SAFETY INFORMATION
- LOTEMAX SM, as with other ophthalmic corticosteroids, is
contraindicated in most viral diseases of the cornea and
conjunctiva including epithelial herpes simplex keratitis
(dendritic keratitis), vaccinia, and varicella, and also in
mycobacterial infection of the eye and fungal diseases of ocular
structures.
- Prolonged use of corticosteroids may result in glaucoma with
damage to the optic nerve, defects in visual acuity and fields of
vision. Steroids should be used with caution in the presence of
glaucoma. If LOTEMAX SM is used for 10 days or longer, IOP should
be monitored.
- Use of corticosteroids may result in posterior subcapsular
cataract formation.
- The use of steroids after cataract surgery may delay healing
and increase the incidence of bleb formation. In those with
diseases causing thinning of the cornea or sclera, perforations
have been known to occur with the use of topical steroids. The
initial prescription and renewal of the medication order should be
made by a physician only after examination of the patient with the
aid of magnification such as slit lamp biomicroscopy and, where
appropriate, fluorescein staining.
- Prolonged use of corticosteroids may suppress the host response
and thus increase the hazard of secondary ocular infections. In
acute purulent conditions, steroids may mask infection or enhance
existing infections.
- Employment of a corticosteroid medication in the treatment of
patients with a history of herpes simplex requires great caution.
Use of ocular steroids may prolong the course and may exacerbate
the severity of many viral infections of the eye (including herpes
simplex).
- Fungal infections of the cornea are particularly prone to
develop coincidentally with long-term local steroid application.
Fungus invasion must be considered in any persistent corneal
ulceration where a steroid has been used or is in use. Fungal
cultures should be taken when appropriate.
- Contact lenses should not be worn when the eyes are
inflamed.
- There were no treatment-emergent adverse drug reactions that
occurred in more than 1% of subjects in the three times daily group
compared to vehicle.
Click here for full Prescribing Information for
LOTEMAX SM.
Important Safety Information for VYZULTA
INDICATION
VYZULTA (latanoprostene bunod ophthalmic solution) 0.024% is
indicated for the reduction of intraocular pressure (IOP) in
patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
- Increased pigmentation of the iris and periorbital tissue
(eyelid) can occur. Iris pigmentation is likely to be
permanent.
- Gradual changes to eyelashes, including increased length,
increased thickness, and number of eyelashes, may occur. These
changes are usually reversible upon treatment discontinuation.
- Use with caution in patients with a history of intraocular
inflammation (iritis/uveitis). VYZULTA should generally not be used
in patients with active intraocular inflammation.
- Macular edema, including cystoid macular edema, has been
reported during treatment with prostaglandin analogs. Use with
caution in aphakic patients, in pseudophakic patients with a torn
posterior lens capsule, or in patients with known risk factors for
macular edema.
- There have been reports of bacterial keratitis associated with
the use of multiple-dose containers of topical ophthalmic products
that were inadvertently contaminated by patients.
- Contact lenses should be removed prior to the administration of
VYZULTA and may be reinserted 15 minutes after administration.
- Most common ocular adverse reactions with incidence ≥2% are
conjunctival hyperemia (6%), eye irritation (4%), eye pain (3%),
and instillation site pain (2%).
Please click here for full Prescribing
Information.
Patients are encouraged to report negative side effects of
these prescription drugs to the FDA. Visit
www.fda.gov/medwatch or call 1-800-FDA-1088.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift
of sight for millions of people around the world – from birth
through every phase of life. Its comprehensive portfolio of
approximately 400 products includes contact lenses, lens care
products, eye care products, ophthalmic pharmaceuticals,
over-the-counter products and ophthalmic surgical devices and
instruments. Founded in 1853, Bausch + Lomb has a significant
global research and development, manufacturing and commercial
footprint with approximately 13,000 employees and a presence in
nearly 100 countries. Bausch + Lomb is headquartered in Vaughan,
Ontario with corporate offices in Bridgewater, New Jersey. For more
information, visit www.bausch.com and connect with us on X,
LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which
may generally be identified by the use of the words “anticipates,”
“hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,”
“will,” “may,” “believes,” “estimates,” “potential,” “target,” or
“continue” and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties discussed in
Bausch + Lomb’s filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch + Lomb undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
*This statement has not been evaluated
by the Food and Drug Administration. This product is not intended
to diagnose, treat, cure or prevent any disease.
References
- XIIDRA significantly reduced symptoms of eye dryness at 2 weeks
in two out of four clinical studies.
- XIIDRA. Prescribing information. Bausch & Lomb Inc;
2023.
© 2024 Bausch + Lomb.
BLS.0079.USA.24
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240528246464/en/
Media Contacts: Kristy Marks kristy.marks@bausch.com
(908) 927-0683 Caryn Marshall caryn.marshall@bausch.com (908)
493-1381
Investor Contact: George Gadkowski
george.gadkowski@bausch.com (877) 354-3705 (toll free) (908)
927-0735
Bausch plus Lomb (NYSE:BLCO)
過去 株価チャート
から 7 2024 まで 8 2024
Bausch plus Lomb (NYSE:BLCO)
過去 株価チャート
から 8 2023 まで 8 2024